BridgeBio Pharma Inc
Q2 2026 Earnings
Market Reaction
Did BBIO Beat Earnings? Q2 2026 Results
BridgeBio Pharma delivered a sharply mixed second quarter, with revenue surging well ahead of expectations while its bottom line fell short, setting up a pivotal stretch heading into a trio of potential FDA approvals. Revenue of $243.68 million topped the $219.71 million consensus by 10.91% and more than doubled from $110.56 million a year ago, a 120.4% year-over-year jump driven overwhelmingly by U.S. Attruby net product revenue of $222.44 million as physicians increasingly initiate treatment-naïve patients on the therapy. The profit picture was harder to swallow: GAAP EPS came in at $-0.78, missing the $-0.5827 consensus by 33.86%, as total operating expenses climbed to $350.75 million, reflecting accelerating SG&A and R&D spend tied to commercial buildout and late-stage pipeline support. Analysts had largely anticipated losses given BridgeBio's pre-launch investment posture, and with three NDAs now under FDA review, including BBP-418 with a November 2026 PDUFA date, a $1 billion preferred equity financing closed July 1 is intended to fund all three launches simultaneously.
- Attruby net product revenue growth driven by treatment-naïve patient segment as physicians increasingly start and keep patients on Attruby
- First-line market share for Attruby continued to climb in Q2 2026
- Royalty revenue increase from BEYONTTRA net product sales in the EU and Japan
- Independent real-world evidence showing 37% reduction in composite cardiovascular events versus tafamidis at six months
“I'm excited by the growing body of evidence continuing to demonstrate Attruby is the drug of choice for all ATTR-CM patients, and particularly for those who are treatment-naïve, including the first-ever demonstration of early, sustained kidney-protective effects in ATTR-CM alongside the cardiac benefit we've established. Furthermore, this was the quarter all three of our pipeline programs, BBP-418, encaleret, and infigratinib, moved from data into active regulatory review, with our first PDUFA date now set for November 27, 2026, which is a level of strategic execution and discipline I'm proud of. Finally, with the $1 billion preferred equity financing we completed, we have a balance sheet sized to run all three launches at full strength, without diverting resources from the development engine that produced them.”
BridgeBio Pharma CEO, on the earnings call
Forward Guidance & Outlook
BridgeBio has three NDAs under FDA review with PDUFA dates spanning late 2026 through mid-2027: BBP-418 for LGMD2I/R9 (November 27, 2026), encaleret for ADH1 (May 8, 2027), and oral infigratinib for achondroplasia (U.S. launch expected mid-2027). The $1 billion preferred equity financing closed July 1, 2026 is intended to fund all three potential launches at full strength. The company plans to submit an MAA to the EMA for oral infigratinib in Q4 2026 and anticipates EU approval in H2 2027. RECLAIM-HP (encaleret in chronic hypoparathyroidism, ~200,000 patients in U.S. and EU) has begun screening with topline data expected late 2027 or early 2028. A Phase 2 update in hypochondroplasia is expected in H2 2026. BridgeBio will host a Commercial Day on October 8, 2026 to discuss launch strategy across its three upcoming launches. The company also plans to explore Attruby's potential in orphan kidney indications and intends to initiate pediatric LGMD2I/R9 studies in H1 2027.
BBIO YoY Financials
BBIO Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.